Tab Application Banner
  • Users Online: 177
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2013  |  Volume : 8  |  Issue : 6  |  Page : 31-35

Outcome measures in rheumatoid arthritis


1 Section of Rheumatology, Institute of Infection and Immunology, Cardiff University School of Medicine, Cardiff University, United Kingdom
2 Section of Rheumatology, Institute of Infection and Immunology, Cardiff University School of Medicine, Cardiff University; Institute of Infection and Immunity, Arthritis Research UK CREATE Centre, Cardiff University School of Medicine, Tenovus Building, Heath Park Campus, Cardiff CF14 4XN, United Kingdom

Correspondence Address:
Ernest H Choy
Section of Rheumatology, Institute of Infection and Immunology, Cardiff University School of Medicine, Cardiff University; Institute of Infection and Immunity, Arthritis Research UK CREATE Centre, Cardiff University School of Medicine, Tenovus Building, Heath Park Campus, Cardiff CF14 4XN
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.injr.2013.11.011

Rights and Permissions

Traditional treatment with conventional Disease Modifying Anti-Rheumatic Drugs (DMARDs) for Rheumatoid Arthritis (RA) aim to suppress inflammation, relieve symptoms and retard joint destruction. Because of the limited efficacy and high risk of toxicity of current treatments, better treatments are needed. For assessing therapeutic efficacy and safety of any new treatment, clinical trials remain the gold standard. In clinical trials, outcome measures are the key tools that allow the impact of any intervention be assessed and compared. Before 1990, RA clinical trials often included 10 or more measures of disease activity. Over the past 20 years, OMERACT has played a critical role in driving global consensus on the development and validation of outcome measures in RA. The RA core data set includes 7 ώ 1 domains (pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, physician/assessor global assessment, radiographs of joints), which should be assessed in all RA clinical trials. ACR Response Criteria, DAS28 and EULAR Response Criteria are the composite measures used in RA clinical trials globally. Fatigue was added to core data set after OMERACT 8 meeting with a major input from RA patients. OMERACT RA flare group is currently working on developing definition of RA flare. The RA core data set and response criteria had a fundamental impact on clinical trials, and are accepted by regulatory authorities in the licensing of new med- ications. They have become the global standard and used consistently in all clinical trials enabling pooling and comparing different clinical trials to facilitate evidence based practice.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed382    
    Printed10    
    Emailed0    
    PDF Downloaded64    
    Comments [Add]    
    Cited by others 1    

Recommend this journal